Skip to main navigation Skip to search Skip to main content

Si-Jun-Zi-Tang potentiates temozolomide's anti-melanoma efficacy and reduces its hepatotoxicity

  • Amy Sze Man Li
  • , Li Wang
  • , Xiao-Yun Fan
  • , Xiao-Qi Wang
  • , Ying Wu
  • , Jia-Ying Wu
  • , Jing-Xuan Bai
  • , Rui-Xuan Han
  • , Jin-Jin He
  • , Xiu-Qiong Fu*
  • , Zhi-Ling Yu*
  • *Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

Abstract

Background:
Malignant melanoma remains a major challenge in oncology, largely due to the limited efficacy and significant toxicity associated with treatments such as temozolomide (TMZ). Si-Jun-Zi-Tang (SJZT), a traditional Chinese medicine formula with documented anti-cancer properties, has shown potential in enhancing chemotherapy effectiveness and reducing treatment-related toxicity.

Purpose:
This study investigated the role of SJZT in improving TMZ treatment outcomes in melanoma.

Methods:
The effects of SJZT on TMZ treatment outcomes were evaluated in melanoma cell lines and mouse models. Cell proliferation, apoptosis, DNA damage, and cell cycle distribution were assessed using CCK-8 assays, Annexin V/PI staining, γ-H2AX immunofluorescence, and flow cytometry, respectively. In vivo antitumor efficacy and hepatotoxicity were evaluated in melanoma-bearing mice. Mechanistic insights were explored via network pharmacology and RNA sequencing, and validated by RT-qPCR, Western blotting, and rescue experiments.

Results:
SJZT enhanced TMZ-induced inhibition of cell proliferation, apoptosis, and DNA strand breaks in melanoma cells. SJZT also attenuated TMZ-induced G2/M arrest, promoting mitotic catastrophe. In mouse models, SJZT enhanced the anti-tumor effects of TMZ and mitigated TMZ-induced hepatotoxicity. Mechanistically, network pharmacology and experimental validation revealed that simultaneous inhibition of Chk1 and promotion of MGMT proteasomal degradation mediated the enhanced anti-melanoma effects of TMZ with SJZT. RNA sequencing and experimental validation demonstrated that TMZ upregulated the bile salt transporter Slc10a1/Ntcp and downregulated detoxifying enzymes Ugt1a1 and Slco1b2/Oatp2, disrupting bile acid homeostasis. Notably, SJZT co-administration reversed these changes, restoring bile acid balance.

Conclusion:
These findings reveal that SJZT can enhance TMZ’s therapeutic efficacy while reducing hepatotoxicity, supporting its use as a promising adjuvant in melanoma treatment.
Original languageEnglish
Article number158012
Number of pages17
JournalPhytomedicine
Volume153
Early online date24 Feb 2026
DOIs
Publication statusPublished - Apr 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

User-Defined Keywords

  • Chinese medicine
  • Chk1
  • Hepatotoxicity
  • MGMT
  • Melanoma
  • Si-Jun-Zi-Tang
  • Temozolomide

Fingerprint

Dive into the research topics of 'Si-Jun-Zi-Tang potentiates temozolomide's anti-melanoma efficacy and reduces its hepatotoxicity'. Together they form a unique fingerprint.

Cite this